Dirigirse a KRAS ((G12C): del mecanismo inhibidor a la modulación de los efectos antitumorales en los pacientes
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Ver abstracta en PubMed
Resumen
Este resumen es generado por máquina.La orientación de las mutaciones KRAS ((G12C), comunes en el cáncer de pulmón, es prometedora. Los nuevos inhibidores están avanzando en la oncología de precisión y mejorando los resultados de los pacientes al dirigirse a las oncoproteínas KRAS.
Área De La Ciencia
- En el campo de la oncología
- Biología molecular
- Química medicinal
Sus Antecedentes
- Las mutaciones KRAS son frecuentes en varios tipos de cáncer, incluidos los pulmonares, colorrectales y pancreáticos.
- La inhibición directa de las oncoproteínas KRAS ha sido un desafío significativo en la terapia del cáncer durante décadas.
- El descubrimiento de las mutaciones de RAS hace casi 40 años sentó las bases para enfoques específicos.
Objetivo Del Estudio
- Revisar los avances recientes en la orientación de las mutaciones KRAS, en particular KRAS ((G12C).
- Discutir el impacto de estos avances en la comprensión de la biología de las oncoproteínas KRAS.
- Destacar el progreso en el desarrollo de estrategias terapéuticas para pacientes con cánceres con mutación KRAS.
Principales Métodos
- Revisión de los estudios preclínicos sobre los inhibidores de KRAS ((G12C).
- Análisis de los datos clínicos emergentes de los ensayos con pacientes.
- Discusión de la biología fundamental de las oncoproteínas KRAS.
Principales Resultados
- Desarrollo de inhibidores específicos dirigidos a la mutación KRAS ((G12C).
- Las mutaciones KRAS ((G12C) se encuentran en aproximadamente el 13% de los adenocarcinomas pulmonares.
- Los datos clínicos emergentes sugieren posibles beneficios terapéuticos para los pacientes.
Conclusiones
- Los avances recientes en la química medicinal han dado lugar a inhibidores eficaces de KRAS (G12C).
- Estos inhibidores están remodelando la comprensión de la biología de las oncoproteínas KRAS.
- Se están logrando avances hacia la mejora de los resultados clínicos de los pacientes con cánceres mutados por KRAS.
Contact us Si estos videos no son relevantes.
Contact us Si estos videos no son relevantes.
Videos de Conceptos Relacionados
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...